Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some statements are supported by the label excerpt (e.g., infections/IBD and that some infection trends relate to higher serum concentrations), but many “most common side effects” claims are not supported by the provided adverse-reaction table/details, and multiple dose-risk/immune-response statements are either unsupported or only partially supported.
Category Scores
Accurate Statements
Adverse reactions in the label include infections (including reported opportunistic infections), inflammatory bowel disease (IBD), hypersensitivity reactions, and eczematous eruptions.
Label support in provided excerpt: 6 (lists Infections, Hypersensitivity Reactions, Inflammatory Bowel Disease, Eczematous Eruptions) and 6.2 (postmarketing opportunistic infections; immune system disorders such as anaphylaxis/angioedema/systemic vasculitis; skin/subcutaneous disorders such as eczematous eruptions).
Unsupported Statements
The most common side effects of Cosentyx include injection site reactions (such as redness, swelling, and pain).
The provided label excerpt (6/6.1/6.2) does not list injection site reactions among adverse reactions, nor does it provide frequency data supporting this as a “most common” adverse effect.
The most common side effects of Cosentyx include upper respiratory tract infections (such as bronchitis and pneumonia).
The provided excerpt includes “upper respiratory tract infection” as an adverse event category occurring in PsO trials (Table 2 shows URTI rates ~2–3% vs placebo ~0.7% through Week 12) and in PsA/AS narratives, but it does not support characterizing URTIs as “most common,” nor does it support the examples (bronchitis/pneumonia) as specifically included in the cited “upper respiratory tract infection” wording.
The most common side effects of Cosentyx include nausea and vomiting.
The provided excerpt reports nausea as an adverse event in AS (narrative) but does not provide label evidence that nausea/vomiting are among the “most common” adverse effects; vomiting is not shown in the provided excerpt.
The most common side effects of Cosentyx include headache.
The provided excerpt states headache occurred at a proportion of at least 2% and higher in adult PsA trials, but it does not support this being among the “most common” side effects, and the excerpt does not provide a “most common” ranking.
The most common side effects of Cosentyx include fatigue.
Fatigue is not present in the provided adverse reaction table (PsO Table 2) or the provided PsA/AS adverse event lists.
The most common side effects of Cosentyx include diarrhea.
Diarrhea appears in PsO Table 2 through Week 12 (4.1% at 300 mg, 2.6% at 150 mg) but the excerpt does not support diarrhea being “most common.”
Higher doses of Cosentyx were associated with a higher risk of adverse events, including injection site reactions and upper respiratory tract infections.
The provided excerpt supports some dose/concentration-related infection trends (e.g., “increasing trend for some types of infection with increasing serum secukinumab concentrations”), but it does not support injection site reactions as a dose-related adverse-event increase, and the excerpt does not provide dose-stratified data establishing higher-dose URTI risk in the manner claimed.
The severity and frequency of Cosentyx side effects may vary depending on the dosage.
While the excerpt mentions an increasing trend for some infections with increasing serum secukinumab concentrations, it does not provide generalized labeling language that severity/frequency of all side effects vary by dosage; thus the broad claim is not fully supported.
Higher doses of Cosentyx may lead to more intense immune responses.
No labeling excerpt provided explicitly supports “more intense immune responses” linked to higher doses.
More intense immune responses from higher doses of Cosentyx can lead to more severe side effects.
No labeling excerpt provided supports a mechanism linking “more intense immune responses” to “more severe side effects.”
A review of clinical trial data and post-marketing surveillance reports suggests that the risk of side effects may increase with higher doses of Cosentyx.
The provided excerpt provides specific dose/concentration-related trends for some infections, but does not support a generalized statement that a review of trial and postmarketing reports shows increased risk of side effects with higher doses.
In a study, patients receiving the highest dose of Cosentyx (300 mg every 4 weeks) had a higher incidence of injection site reactions compared to those receiving lower doses.
The provided excerpt does not include injection site reaction data or any statement comparing injection site reaction incidence between 300 mg and lower doses.
Higher doses of Cosentyx may be more effective.
The provided excerpt contains efficacy response data in PsA (ACR responses) comparing 150 mg vs 300 mg, but the claim is framed generally as “may be more effective” without tying to a specific label statement about effectiveness vs dose; the excerpt shows some response differences but does not explicitly support a generalized “higher doses are more effective” conclusion.
Higher doses of Cosentyx carry a higher risk of side effects.
The excerpt supports an increasing trend for some infections with increasing serum concentrations, but it does not support a broad label-backed statement that higher doses carry a higher risk of side effects overall (and particularly not for injection site reactions).
Contradictions
Important Omissions
Approved indications, contraindications, boxed warnings, and detailed warnings/precautions are not evaluated because the provided excerpt does not include the Indications/Usage section text or the boxed warning/warnings sections beyond the adverse-reaction headings.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements overgeneralize or assert dose-related increases in specific adverse events (e.g., injection site reactions) and label “most common” adverse effects without support from the provided excerpt, which could mislead about the true commonality and dose-risk relationship.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Overstated “most common” adverse effects and unsupported/overgeneralized dose-risk and immune-response statements not substantiated by the provided label excerpt.
Suggested Improvement
Limit claims to adverse reactions and dose/concentration-related trends explicitly supported in the provided label text (e.g., infections overall rates and the stated increasing trend for some infection types with increasing serum concentrations), and avoid labeling specific items as “most common” or asserting injection-site dose relationships unless explicitly shown in the excerpt.